5.7058
전일 마감가:
$5.77
열려 있는:
$5.75
하루 거래량:
598.94K
Relative Volume:
0.48
시가총액:
$589.57M
수익:
-
순이익/손실:
$-168.09M
주가수익비율:
-2.6294
EPS:
-2.17
순현금흐름:
$-138.01M
1주 성능:
-4.60%
1개월 성능:
+0.26%
6개월 성능:
-34.50%
1년 성능:
-73.09%
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
KURA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KURA
Kura Oncology Inc
|
5.71 | 589.57M | 0 | -168.09M | -138.01M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
451.98 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
537.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
323.52 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
553.86 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.50 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-10-24 | 개시 | UBS | Buy |
2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
2023-12-22 | 개시 | Mizuho | Buy |
2023-08-11 | 개시 | BofA Securities | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Perform |
2023-05-17 | 개시 | BTIG Research | Buy |
2023-01-31 | 개시 | Stifel | Buy |
2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
2022-02-15 | 개시 | Jefferies | Buy |
2021-05-05 | 재개 | Credit Suisse | Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2020-12-07 | 재확인 | H.C. Wainwright | Buy |
2020-12-03 | 개시 | Stifel | Buy |
2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2020-07-07 | 개시 | Credit Suisse | Outperform |
2020-05-05 | 개시 | Barclays | Overweight |
2019-07-18 | 개시 | Deutsche Bank | Buy |
2018-11-09 | 개시 | Piper Jaffray | Overweight |
2018-08-01 | 개시 | H.C. Wainwright | Buy |
2016-10-13 | 재개 | Leerink Partners | Outperform |
2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
2015-12-30 | 개시 | Oppenheimer | Outperform |
2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Canada
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Kura Oncology and Kyowa Kirin Report Strong Results from KOMET-007 Trial of Ziftomenib in Newly Diagnosed AML Patients - Nasdaq
Kura Oncology reports positive data for AML treatment ziftomenib - Investing.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly ... - Enidnews.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - Yahoo Finance
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment - Investing.com
Cantor Fitzgerald Forecasts Kura Oncology FY2026 Earnings - Defense World
KURA Stock Rises More Than 15% This Past Week: Here's Why - MSN
Kura Oncology at Goldman Sachs Conference: Strategic Insights on ZIFTOMENIB - Investing.com Canada
Transcript : Kura Oncology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Stockholders Approve Equity Plan Amendment - TipRanks
Kura Oncology Grants Stock Options To New Hires Under Inducement Plan - Nasdaq
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KUR - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Expands Cancer Research Team with Strategic Stock Options for 5 Key New Hires - Stock Titan
Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Kura Oncology at Jefferies Conference: Strategic Advancements in AML By Investing.com - Investing.com Canada
**citizens jmp reiterates market outperform rating on kura oncology stock** - Investing.com UK
Two Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It - insights.citeline.com
Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06 - marketscreener.com
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
KURA: Optimism for Kura Oncology's Menin Inhibitor Grows with FDA Priority Review | KURA Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating for Kura Oncology stock By Investing.com - Investing.com Nigeria
Kura Oncology reports positive trial results for AML treatment By Investing.com - Investing.com South Africa
Kura Oncology at ASCO: Strategic Moves in AML Treatment By Investing.com - Investing.com Canada
Kura Oncology reports positive trial results for AML treatment - Investing.com Australia
KURA: Promising Results for Kura Oncology's AML Therapy at ASCO Meeting | KURA Stock News - GuruFocus
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Kura Oncology Inc 주식 (KURA) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
FORD KATHLEEN | Chief Operating Officer |
May 19 '25 |
Sale |
6.28 |
1,558 |
9,777 |
21,367 |
자본화:
|
볼륨(24시간):